Xiao-Ran Liu

List of Publications by Year
in descending order

29	436	840776	752698
papers	citations	11 h-index	20 g-index

33	33	33	894
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Identification of mutation patterns and circulating tumour DNA-derived prognostic markers in advanced breast cancer patients. Journal of Translational Medicine, 2022, 20, 211.	4.4	8
2	Efficacy and safety of initial five years of adjuvant endocrine therapy in postmenopausal hormone receptor-positive breast cancer: A systematic review and network meta-analysis.. Journal of Clinical Oncology, 2022, 40, 535-535.	1.6	0
3	Peripheral cytotoxic T lymphocyte predicts first-line progression free survival in HER2-positive advanced breast cancer. Breast, 2021, 55, 7-15.	2.2	5
4	Clinicopathological features and prognosis of patients with pregnancyâ€associated breast cancer: A matched case control study. Asia-Pacific Journal of Clinical Oncology, 2021, 17, 396-402.	1.1	9
5	Prognostic Value of the TP53 Mutation Location in Metastatic Breast Cancer as Detected by Next-Generation Sequencing. Cancer Management and Research, 2021, Volume 13, 3303-3316.	1.9	5
6	Bilateral breast cancer in China: A 10â€year singleâ€center retrospective study (2006â€“2016). Cancer Medicine, 2021, 10, 6089-6098.	2.8	6
7	Cell-free DNA comparative analysis of the genomic landscape of first-line hormone receptor-positive metastatic breast cancer from the US and China. Breast Cancer Research and Treatment, 2021, 190, 213-226.	2.5	2
8	Prognostic Value of Plasma HER2 Gene Copy Number in HER2-Positive Metastatic Breast Cancer Treated with First-Line Trastuzumab . OncoTargets and Therapy, 2020, Volume 13, 4385-4395.	2.0	6
9	Methylome Variation Predicts Exemestane Resistance in Advanced ER‹sup›+‹/sup› Breast Cancer. Technology in Cancer Research and Treatment, 2020, 19, 153303381989633.	1.9	5
10	Efficacy of platinum in advanced triple-negative breast cancer with germline BRCA mutation determined by next generation sequencing. Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research, 2020, 32, 149-162.	2.2	12
11	Phase I dose-escalation and expansion study of PARP inhibitor, fluzoparib (SHR3162), in patients with advanced solid tumors. Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research, 2020, 32, 370-382.	2.2	18
12	Cell-free DNA comparative analysis of hormone receptor-positive, first-line metastatic breast cancer genomic landscape in the United States and China.. Journal of Clinical Oncology, 2020, 38, 1059-1059.	1.6	11
13	Plasma microRNAs Predict Chemoresistance in Patients With Metastatic Breast Cancer. Technology in Cancer Research and Treatment, 2019, 18, 153303381982870.	1.9	26
14	Efficacy of platinum-based regimens as the first-line therapy in Chinese patients with advanced TNBC and deleterious BRCA1/2 mutations.. Journal of Clinical Oncology, 2019, 37, e12565-e12565.	1.6	0
15	Combined peripheral natural killer cell and circulating tumor cell enumeration enhance prognostic efficiency in patients with metastatic triple-negative breast cancer. Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research, 2018, 30, 315-326.	2.2	14
16	Liquid Biospy: Noninvasive Diagnosis and Molecular Phenotyping of Breast Cancer through Microbeadâ€Assisted Flow Cytometry Detection of Tumorâ€Derived Extracellular Vesicles (Small Methods) Tj ETQq1 1 0 rgBT /Overlock	8.6	
17	Noninvasive Diagnosis and Molecular Phenotyping of Breast Cancer through Microbeadâ€Assisted Flow Cytometry Detection of Tumorâ€Derived Extracellular Vesicles. Small Methods, 2018, 2, 1800122.	8.6	20
18	Detection, dynamic monitoring, and resistance mechanism exploration of genomic alterations in circulating cell free tumor DNA (ctDNA) in Chinese metastatic breast cancer (mBC).. Journal of Clinical Oncology, 2018, 36, 1080-1080.	1.6	43

#	Article	IF	Citations
19	Methylomes variation to predict exemestane resistance in advanced breast cancer.. Journal of Clinical Oncology, 2018, 36, e24029-e24029.	1.6	0
20	Plasma PIK3CA ctDNA specific mutation detected by next generation sequencing is associated with clinical outcome in advanced breast cancer. American Journal of Cancer Research, 2018, 8, 1873-1886.	1.4	5
21	Identification of recurrent ‹scp›BRCA‹/scp›1 mutation and its clinical relevance in Chinese Tripleâ€negative breast cancer cohort. Cancer Medicine, 2017, 6, 547-554.	2.8	11
22	Identification of high independent prognostic value of nanotechnology based circulating tumor cell enumeration in first-line chemotherapy for metastatic breast cancer patients. Breast, 2017, 32, 119-125.	2.2	19
23	Peptide-Functionalized Nanomaterials for the Efficient Isolation of HER2-Positive Circulating Tumor Cells. ACS Applied Materials & Interfaces, 2017, 9, 18423-18428.	8.0	47
24	BRM/SMARCA2 promotes the proliferation and chemoresistance ofÂpancreatic cancer cells by targeting JAK2/STAT3 signaling. Cancer Letters, 2017, 402, 213-224.	7.2	55
25	Precisely Enumerating Circulating Tumor Cells Utilizing a Multi-Functional Microfluidic Chip and Unique Image Interpretation Algorithm. Theranostics, 2017, 7, 4710-4721.	10.0	14
26	Methylation signatures of circulating tumor DNA for hormone therapy response in ER+ breast cancer patients (pts).. Journal of Clinical Oncology, 2017, 35, e12542-e12542.	1.6	0
27	Combined peripheral natural killer (NK) cell and circulating tumor cell (CTC) enumeration to enhance prognostic efficiency in patients (pts) with triple-negative breast cancer (TNBC).. Journal of Clinical Oncology, 2017, 35, 1105-1105.	1.6	0
28	Hedgehog Signaling Regulates Epithelial-Mesenchymal Transition in Pancreatic Cancer Stem-Like Cells. Journal of Cancer, 2016, 7, 408-417.	2.5	73
29	Efficacy and safety of trastuzumab combined with chemotherapy for first-line treatment and beyond progression of HER2-overexpressing advanced breast cancer. Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research, 2016, 28, 330-338.	2.2	17